
We are developing a new generation of targeted immunotherapies that  attack solid tumors, and then teach the immune system to hunt down cancer cells elsewhere in the body.


Pioneering the Future
Calidi Biotherapeutics and City of Hope announce first patients dosed in a Phase 1 clinical trial, funded by the California Institute of Regenerative Medicine (CIRM), evaluating neural stem cells engineered to carry an oncolytic virus, CLD-101, in recurrent high-grade glioma patients.
Read More
Science
Discover the future of biotherapeutics with Calidi. Pioneering innovative solutions for solid tumors.

Company Overview
Take a glimpse into Calidi's headquarters, based in San Diego, California, including members of our exceptional team. This video also highlights the latest updates on the company's Clinical Trials and path to becoming a publicly traded company.
Investors
Join us on our journey towards creating a world free from the threat of cancer.

Latest News
Press Release
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones
November 20, 2023
Discover More
Discover More
Press Release
Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Result
November 14, 2023
Discover More
Discover More
Press Release
Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)
November 3, 2023
Discover More
Discover More